CeraVe Moisturizing Cream vs Vanicream Moisturizing Cream: Formula, Packaging, Price, and Evidence Compared

Evidence: E2 — independently cross-checked across the exact U.S. Target listings, current manufacturer pages, independent certification records, U.S. labeling and advertising rules, moisturizer research, product-specific records, and the bounded Article 11 evaluation method

Risk scope: R1 — formula, package, evidence, and price interpretation that may affect spending; no diagnosis, treatment, reaction prediction, or individualized safety advice

Direct observation: Not performed; Formula Clarity did not purchase, open, dispense, weigh, photograph, smell, feel, or use either product

Expert review: Not required for the retained R1 scope; not claimed

Products and prices checked: July 25, 2026, U.S. market

Key limitation: The pair is matched by seller, market, date, general product role, and non-pump format, but the net-quantity labels use different bases—16 fl oz versus 16 oz—and no direct head-to-head test establishes texture, package performance, tolerability, efficacy, or value

Next review: Before any CMS preview, after a material formula, package, price, retailer, certification, study, Product A/B binding, Article 11 method, or PDR-009/PDR-013 change, and no later than July 25, 2027

Quick answer

Neither cream is a universal winner. In the exact Target snapshot, Vanicream’s selected non-pump listing cost $13.19, which was $2.80 less than CeraVe’s $15.99 listing. CeraVe declares a broader formula with glycerin, dimethicone, three named ceramides, sodium hyaluronate, cholesterol, and petrolatum. Vanicream displays a shorter petrolatum-led list with sorbitol and propylene glycol. Those differences can match different label priorities, but they do not prove better hydration, gentleness, texture, package hygiene, personal suitability, or long-term value.

Key facts and unknowns

The comparison is useful only when the exact objects stay visible:

both listings were checked at Target for the U.S. market on the same date;
both selected objects are the non-pump versions, while separate pump SKUs exist;
CeraVe’s page uses 16 fl oz; Vanicream’s page uses 16 oz;
the sticker-price difference is directly comparable, but cost per milliliter or cost per gram is not established from those labels;
both formulas declare water, petrolatum, cetearyl alcohol, and ceteareth-20;
CeraVe displays 24 ingredient names; Vanicream’s current Target and brand lists display 10, while Vanicream’s FAQ says “only 11 ingredients” and some other records add BHT;
both products appear in the National Eczema Association directory, but the Seal is not a personal-suitability guarantee;
no first-party package, dispensing, sensory, stability, contamination, or use observation was performed;
no exact head-to-head finished-product study was found for this matched pair;
Product A/B approval, the project-wide price method, active-WIP admission, CMS execution, and public release remain separate gates.

Exact comparison set

Field	CeraVe Product A candidate	Vanicream Product B candidate
Product	CeraVe Moisturizing Cream	Vanicream Moisturizing Cream
Market	United States	United States
Selected size label	16 fl oz	16 oz
Selected package	Non-pump Target listing	Non-pump Target listing
Target identifier	TCIN 13977967	TCIN 14768513
UPC	3606000537668	345334300014
DPCI	037-12-1958	037-12-2609
Checked date	July 25, 2026	July 25, 2026
Displayed price	$15.99	$13.19
Direct observation	Not performed	Not performed

The pair is intentionally narrow. A pump version, refill, different size, different market, marketplace seller, old package, or future reformulation is a different comparison object until version parity is checked.

Criteria declared before comparing

This page compares seven dimensions:

exact identity and version control;
declared formula and formula-role context;
claim wording and independent directory evidence;
package facts that can be seen on current listings;
same-retailer sticker price and its limits;
product-specific evidence and study-transfer limits;
the buyer constraints each record can support without declaring a universal winner.

Ingredient count, review score, affiliate availability, brand popularity, and unsupported “sensitive skin” assumptions are not scoring criteria.

Comparison at a glance

Dimension	CeraVe	Vanicream	Supported interpretation
Formula disclosure	24 displayed names	10 displayed names, with a separate 10-versus-11/BHT source conflict	Different disclosure patterns; count is not quality
Humectant-related names	Glycerin; Sodium Hyaluronate	Sorbitol; Propylene Glycol	Both declare water-binding context through different materials
Occlusive/conditioning context	Petrolatum; Dimethicone	Petrolatum; Simethicone	Both declare occlusive or conditioning context; amounts and performance are unknown
Ceramide/lipid context	Ceramide NP/AP/EOP; Cholesterol; Phytosphingosine	No named ceramides in the captured list	CeraVe matches a “named ceramide/lipid declaration” constraint; no efficacy verdict follows
Claims	Ceramides, hyaluronic acid, MVE, 24-hour hydration, fragrance-free, non-comedogenic	Fragrance- and masking-fragrance-free, short-list positioning, non-comedogenic, sensitive-skin positioning	First-party wording, not independent outcome proof
Independent directory	NEA listing	NEA listing	Directory presence for both; not a guarantee for an individual
Selected package	Non-pump; separate pump SKU	Non-pump; separate pump SKU	Package identities are comparable; performance was not tested
Same-retailer sticker price	$15.99	$13.19	Vanicream was $2.80 lower in this snapshot
Quantity basis	16 fl oz	16 oz	Do not convert the snapshot into a standardized per-mL or per-gram value verdict
Exact comparative evidence	No exact pair trial found	No exact pair trial found	No evidence-based performance winner

Formula comparison: shared structure, different declarations

What both lists share

The captured declarations both include:

water
petrolatum
cetearyl alcohol
ceteareth-20

This shared set supports a limited interpretation: both are water-containing cream systems with an occlusive ingredient and fatty-alcohol/emulsifier context. It does not establish equal petrolatum amount, equal emulsion structure, equal preservation, equal spread, equal wear, or equal finished-product effect.

FDA’s ingredient-declaration rules support identity and limited order context, not exact percentages. Ingredients at one percent or less can appear in any order after the higher-concentration ingredients, so the visible list cannot be used to reconstruct a precise formula or a reliable one-percent line.

CeraVe’s broader declared formula context

The captured CeraVe list additionally includes:

Glycerin and Sodium Hyaluronate;
Caprylic/Capric Triglyceride, Cetyl Alcohol, and other structural or emollient-related materials;
Dimethicone;
Ceramide NP, Ceramide AP, and Ceramide EOP;
Cholesterol and Phytosphingosine;
a broader set of rheology, chelation, antioxidant, buffer, and preservation-related ingredients.

That supports a richer declared formula-role map. It does not disclose the amount of any ceramide, the ceramide-to-cholesterol ratio, MVE structure, delivery, rheology, package compatibility, sensory performance, or superiority.

Vanicream’s shorter petrolatum-led declaration

The current Target and Vanicream pages display:

water
petrolatum
sorbitol
cetearyl alcohol
propylene glycol
ceteareth-20
simethicone
glyceryl stearate
PEG-30 stearate
sorbic acid

This supports a petrolatum-led occlusive context, sorbitol and propylene-glycol humectant context, and a compact public declaration. It does not prove simpler manufacturing, lower irritation risk, stronger occlusion, easier preservation, better tolerability, or better performance.

A material conflict must remain visible: Vanicream’s own FAQ says the product has “only 11 ingredients,” while the displayed product list contains 10 names. Some retailer or directory records have also included BHT. This comparison does not choose a hidden eleventh ingredient or silently merge versions. The package intended for purchase remains the operational source.

Why ingredient count does not select a winner

A 24-name list is not automatically more advanced, and a 10-name list is not automatically gentler. Count ignores:

exact amount and grade;
raw-material blends;
manufacturing process;
pH and physical structure;
preservation challenge results;
package compatibility;
stability after opening;
sensory properties;
individual exposure history;
finished-product evidence.

The supported conclusion is that the formulas disclose materially different ingredient patterns, not that one pattern is universally better.

Claims, fragrance wording, and independent directory evidence

CeraVe’s retailer and brand pages emphasize three named ceramides, hyaluronic acid, petrolatum, dimethicone, MVE technology, long-lasting hydration, fragrance-free status, and non-comedogenic positioning.

Vanicream’s pages emphasize freedom from fragrance and masking fragrance, a short formula, petrolatum-led moisturization, non-comedogenic positioning, and avoidance of several commonly marketed ingredient categories.

These are brand or retailer claims. They must be attributed to the claimant rather than presented as independent confirmation. FDA does not pre-approve ordinary cosmetic labels, and FTC substantiation standards require a reasonable basis for objective advertising claims.

Both named products appear in the National Eczema Association product directory. The directory provides a meaningful independent record of program participation, but its own disclaimer leaves ingredient checking and personal suitability with the user and healthcare professional. Directory status therefore cannot decide which product is safer, gentler, or more appropriate for a particular person.

Packaging comparison without pretending to test either jar

The selected products are the non-pump listings. Target also shows a separate 16-ounce pump version for each product.

That allows several factual statements:

a pump and non-pump choice exists for both product families;
the selected non-pump SKUs have different identifiers from the pump SKUs;
the pump listings had higher displayed prices on the checked pages;
research, CMS, pricing, and future observation records must not combine those packages.

It does not allow conclusions about:

contamination exposure;
seal integrity;
opening diameter;
one-handed use;
pump priming or clogging;
dose repeatability;
residual waste;
travel leakage;
accessibility;
protection from air, light, moisture, or repeated opening.

No package was inspected. A package-convenience or hygiene winner would require an E3 observation protocol or relevant package-performance evidence.

Price comparison: one valid number and several invalid shortcuts

On July 25, 2026, Target displayed:

CeraVe selected non-pump listing = $15.99
Vanicream selected non-pump listing = $13.19
sticker-price difference = $2.80

The supported price conclusion is narrow: Vanicream’s selected listing had the lower pre-tax sticker price by $2.80 at the same retailer on the same date.

The snapshot does not establish a value winner because:

CeraVe is labeled 16 fl oz, while Vanicream is labeled 16 oz;
density and actual usable quantity were not measured;
retailer-displayed unit prices do not resolve the mass-versus-volume basis;
taxes, shipping, membership, coupons, subscriptions, local stock, and checkout conditions are excluded;
cost per application requires a measured or disclosed dose;
package waste and dispensing behavior were not observed;
future price and seller conditions can change;
PDR-013 has not approved the project-wide price method.

Therefore, this page does not claim that Vanicream is “21% better value,” that CeraVe’s extra $2.80 is justified, or that either product is the lowest-cost option.

Product-specific evidence: relevant, but not head-to-head

Article 12 CeraVe Moisturizing Cream analysis records a small randomized within-patient moisturizer study that included CeraVe Moisturizing Cream. The study was underpowered and did not compare the exact current Target CeraVe SKU against the selected Vanicream SKU under this buyer rubric.

Article 13 Vanicream Moisturizing Cream analysis records a historical physicochemical study that included Vanicream Moisturizing Skin Cream and a small trial-registry record naming a Vanicream cream. Those records are tied to their tested samples, methods, dates, and outcomes. They are not direct evidence about the current Target non-pump object or a comparative consumer outcome.

The evidence sets are not symmetric:

one product-named study does not automatically outweigh a different type of product-named record;
a pH or hydrophilic-index measurement is not the same outcome as a human barrier measure;
a trial registry is not a completed result;
neither evidence set measures this exact pair’s texture, package use, pilling, facial wear, preference, current price, or personal suitability.

No exact head-to-head finished-product study was located for the selected pair. That absence blocks an evidence-based performance winner; it does not prove the products perform the same.

Constraint-based decision matrix

The comparison can support conditional label decisions:

Buyer’s stated constraint	Better-documented match	What the match does not prove
Wants three named ceramides, sodium hyaluronate, cholesterol, and phytosphingosine declared	CeraVe	Better barrier outcome, tolerability, or sensory performance
Wants a shorter displayed ingredient declaration	Vanicream	Gentleness, safety, easier preservation, or superior performance
Wants the lower same-retailer sticker price in this snapshot	Vanicream	Lower standardized cost, lower cost per use, or better value
Wants an NEA-listed product	Both	Personal suitability or medical recommendation
Wants a non-pump 16-size retail object	Both	Same net-quantity basis or same package behavior
Wants evidence of actual texture, absorption, residue, odor, pilling, or dispensing	Neither	Those traits require direct observation
Wants a proven head-to-head performance winner	Neither	No exact matched trial supports that conclusion
Wants advice for a diagnosed condition, prescription routine, pregnancy, procedure, or serious reaction	Neither; outside this comparison	Requires a different evidence and review process

This matrix answers only the declared constraint. It is not a ranking system.

What the available evidence cannot decide

The current records cannot determine:

which cream hydrates more under a shared protocol;
which feels lighter, richer, greasier, tackier, or faster-absorbing;
which pills less under sunscreen or makeup;
which package is cleaner, easier, more accessible, or less wasteful;
which current lot has better stability or preserved quality;
which product is less likely to irritate, clog pores, or trigger a reaction;
which is suitable for an individual;
which is the better facial or body moisturizer;
whether CeraVe’s broader declaration justifies the price difference;
whether Vanicream’s shorter declaration improves tolerability;
a standardized cost per gram, milliliter, or use;
a universal or “best overall” winner.

Comparison verdict

The bounded evidence supports a conditional decision, not a universal winner:

Choose by the constraint you can actually verify. CeraVe’s label is the clearer match when the purchase requirement is a formula that declares three named ceramides, sodium hyaluronate, cholesterol, phytosphingosine, dimethicone, and petrolatum. Vanicream’s label is the clearer match when the requirement is a shorter petrolatum-led declaration and the lower same-retailer sticker price in this snapshot. Neither record proves better performance, gentleness, package experience, personal suitability, or long-term value.

This is a decision_supported result under the Article 11 method for the exact bounded question. It is not PDR-009 approval, a product recommendation, a price-value verdict, CMS authorization, or publication approval.

Methodology and evidence limitations

Formula Clarity applied the gate-first Article 11 method to two exact U.S. Target objects. Identity, ordinary evidence, R1 risk, no-observation, and package-scope comparison checks pass for a repository candidate. The candidate universe is bound to the exact successor PDR-009 decision for this Article 14 transaction. No price-value verdict is requested because PDR-013 v003 remains descriptive only and standardized quantity inputs are absent. No material commercial relationship or affiliate link is present.

Public pages can change. Ingredient declarations may differ by market, batch, package, or update cycle. Vanicream has a documented ingredient-count conflict. CeraVe’s 16 fl oz and Vanicream’s 16 oz labels are not treated as the same measurement basis. No physical unit was inspected, and no head-to-head test was performed.

Before CMS work, Codex must recheck the exact Article 11 method, accepted Article 12 and Article 13 successor bindings, current prices/formulas, and all Article 14 PDR/validator records. The CMS transaction remains gated by the exact successor runbook and observed D/P evidence; no testing, recommendation, value winner, or unsupported formula equivalence is added.